Free Newsletter
Pfizer bankrolls a stem cell start-up
Pfizer is bankrolling a biotech start-up that will concentrate on developing new stem cell therapies for eye disease. Scripps Research Institute's Martin Friedlander has undertaken animal studies that identified bone and blood-marrow stem cells that could repair damaged blood vessels in the eye. And the new company, EyeCyte, will be responsible for advancing that research into the clinic. Pfizer is investing $3 million in the company and has an option to buy it if continues to look promising.
"Pfizer has put its flag in the ground that there is a future in regenerative medicine," said Pfizer's Corey Goodman.
- read the report from Forbes
Related Articles:
Pfizer blazes new research path with university deal
Pfizer to invest $50M in biotech start-ups
A look inside Pfizer's biotech center
Pfizer hires new R&D chief, launches biotech center
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: